WaveMan
WaveMan · Company
PTN · Palatin Technologies Inc
> Search tickers & screens ⌘K
LIVE
← All companies

PTN Palatin Technologies (PTN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0000911216
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
13
13F, latest reported quarter

Palatin Technologies insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for PALATIN TECHNOLOGIES INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
WILLS STEPHEN T
Executive VP and CFO/COO
SELL
2025-12-29 SECtraded 2025-12-24
565
$9.5K
-64.7%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (7 buys, 4 sales), the last on Aug 1, 2024.
  • +8.1% median (+8.1% mean) 90-day return after 2 previous buys.
  • The trade is 0.9% of the 63,488 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive VP and CFO/COO WILLS STEPHEN T sold about $9.5K of PTN on Dec 24, 2025, the largest insider sale at the company since 2024; 13 funds added in the latest 13F quarter.
DEVEER ROBERT K JR
Director
BUY
2025-05-12 SECtraded 2025-05-07
100,000
$10.0K
+13.6%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (1 buy, 7 sales), the last on Apr 11, 2024.
  • The trade is 72.4% of the 138,065 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEVEER ROBERT K JR bought about $10.0K of PTN on May 7, 2025, the largest insider purchase at the company since 2024; 13 funds added in the latest 13F quarter.
WILLS STEPHEN T
Executive VP and CFO/COO
SELL
2024-08-02 SECtraded 2024-08-01
2,500
$4.1K
-93.2%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (7 buys, 2 sales), the last on Dec 6, 2023.
  • +8.1% median (+8.1% mean) 90-day return after 2 previous buys.
  • The trade is 1.1% of the 235,456 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive VP and CFO/COO WILLS STEPHEN T sold about $4.1K of PTN on Aug 1, 2024; 13 funds added in the latest 13F quarter.
WILLS STEPHEN T
Executive VP and CFO/COO
SELL
2024-08-02 SECtraded 2024-08-01
2,499
$4.1K
-93.2%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (7 buys, 2 sales), the last on Dec 6, 2023.
  • +8.1% median (+8.1% mean) 90-day return after 2 previous buys.
  • The trade is 1.1% of the 237,956 shares held after it.
  • No other insider sold within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive VP and CFO/COO WILLS STEPHEN T sold about $4.1K of PTN on Aug 1, 2024; 13 funds added in the latest 13F quarter.
DEVEER ROBERT K JR
Director
BUY
2024-04-11 SEC
6,000
$12.7K
-94.7%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Mar 6, 2024.
  • The trade is 14.7% of the 40,845 shares held after it.
  • No other insider bought within 30 days.
  • 13 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DEVEER ROBERT K JR bought about $12.7K of PTN on Apr 11, 2024, the largest insider purchase at the company since 2021; 13 funds added in the latest 13F quarter.
30 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 25 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
13 funds bought in last quarter
below 77% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-63.5% net margin
below 52% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
23.3% of the float short (float per yahoo 2026-10-26) · 8.0 days to cover · settled 2026-09-30
more than 95% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch PTN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-16.1%12M
-16%+109%+234%+360%2025-102025-122026-022026-042026-062026-082026-10 2025-12-24 · WILLS STEPHEN T sold $9.5K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns PTN: institutional holders (13F)

13F holdings, latest reported quarter
Driehaus Capital Management LLC
166,713 sh
$1.8M
Jupiter Topco LLC
140,000 sh
$1.5M
Logos Global Management LP
130,000 sh
$1.4M
RA CAPITAL MANAGEMENT, L.P.
62,124 sh
$670.3K
Balyasny Asset Management L.P.
41,110 sh
$443.6K

Congress trades in PTN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

PTN planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

PTN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$57.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$3.7K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$124.8K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$204.0K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$36.7K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$43.7K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 2
2 active
1
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Dr. Spana
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$738.5K
$96.1K
$688.0K
-98%
n/a
2023
$1.4M
$661.0K
$1.4M
-71%
n/a
2022
$1.3M
$283.9K
$1.2M
-69%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 13 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

PTN financials

Net margin
-63.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$13.2M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-63.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
0.05x
long-term debt only, 2019-06-30 (85 months older than the period end); equity 2026-06-30
Cash flow to debt
-40.65x
TTM operating cash flow over long-term debt only, 2019-06-30 (85 months older than the period end)
Return on equity
-877.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-142.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-863.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.9M
market value at close 2026-10-23 on 2026-09-25 shares, plus long-term debt only, 2019-06-30 (85 months older than the period end), minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2026-062025-062024-062023-06
Revenue$13.2M$0$4.5M$4.9M
Operating income-$8.7M-$17.5M-$22.5M-$32.5M
Net income-$8.4M-$17.3M$29.7M$36.2M
EPS (diluted)-2.96-32.15-101.16n/a
Operating cash flow-$13.5M-$21.3M-$31.5M-$29.3M
Cash$7.5M$2.6M$9.5M$11.0M
SEC XBRL, fiscal years, as known on 2026-10-27

PTN Stock Sonar score 4/7 axes

Find similar shapesCompare

PTN ranks highest on financial health (38th percentile) and institutional and government (23rd), and lowest on risk and compliance (7th), among Pharma & Biotech peers.

Profitability
7
Inputs
  • Return on equity-877.5% · 5 pct, sector of 545
  • Return on assets-142.1% · 16 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-863.0% · 1 pct, sector of 576
Financial health
38
Inputs
  • Debt to equity0.05x · 61 pct, sector of 352
  • Cash flow to debt-40.65x · 14 pct, sector of 371
Institutional and government
23
Inputs
  • Funds adding, latest quarter13 · 23 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
7
Inputs
  • Short interest, % of float+23.3% · 10 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+54.2% · 4 pct, sector of 511
3 not measured: Growth, Insider conviction, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies